1-2020

Antibiotic Drug Nanocarriers for Probing of Multidrug ABC Membrane Transporter of *Bacillus subtilis*

Pavan Kumar Cherukuri
Preeyaporn Songkiatisak
Feng Ding
Jeam-Michel Jault
Xiao-Hong Nancy Xu

Follow this and additional works at: https://digitalcommons.odu.edu/chemistry_fac_pubs

Part of the Biochemistry Commons, Chemistry Commons, and the Molecular Biology Commons
Antibiotic Drug Nanocarriers for Probing of Multidrug ABC Membrane Transporter of Bacillus subtilis

Pavan Kumar Cherukuri,§ Preeyaporn Songkiatisak,§ Feng Ding,§ Jean-Michel Jault, and Xiao-Hong Nancy Xu*

ABSTRACT: Multidrug membrane transporters can extrude a wide range of substrates, which cause multidrug resistance and ineffective treatment of diseases. In this study, we used three different sized antibiotic drug nanocarriers to study their size-dependent inhibitory effects against Bacillus subtilis. We functionalized 2.4 ± 0.7, 13.0 ± 3.1, and 92.6 ± 4.4 nm silver nanoparticles (Ag NPs) with a monolayer of 11-amino-1-undecanethiol and covalently linked them with antibiotics (ofloxacin, Ofx). The labeling ratios of antibiotics with NPs are 8.6 × 10^2, 9.4 × 10^3, and 6.5 × 10^3 Oflox molecules per NP, respectively. We designed cell culture medium in which both BmrA and ΔBmrA cells grew and functioned normally while ensuring the stabilities of nanocarriers (nonaggregation). These approaches allow us to quantitatively study the dependence of their inhibitory effect against two isogenic strains of B. subtilis, WT (normal expression of BmrA) and ΔBmrA (deletion of bmrA), upon the NP size, antibiotic dose, and BmrA expression. Our results show that the inhibitory effects of nanocarriers highly depend on NP size and antibiotic dose. The same amount of Oflox on 2.4 ± 0.7, 13.0 ± 3.1, and 92.6 ± 4.4 nm nanocarriers shows the 3× lower, nearly the same, and 10× higher inhibitory effects than that of free Oflox, against both WT and ΔBmrA, respectively. Control experiments of the respective sized AgMUNH2 NPs (absence of Oflox) show insignificant inhibitory effects toward both strains. Taken together, the results show multiple factors, such as labeling ratios, multivalent effects, and pharmacodynamics (Oflox localization and distribution), which might play the roles in the size-dependent inhibitory effects on the growth of both WT and ΔBmrA strains. Interestingly, the inhibitory effects of nanocarriers are independent of the expression of BmrA, which could be attributed to the higher efflux of nanocarriers by other membrane transporters in both strains.

INTRODUCTION

ATP-binding cassette (ABC) membrane transporters are one of the largest membrane transport superfamilies, and they exist in all living organisms and play highly significant roles in biological functions.1−7 The ABC membrane transporters can selectively transport a wide variety of substrates across cellular membranes, even though they share a common modular architecture, two transmembrane domains (TMDs) and two nucleotide-binding domains (NBDs). TMDs exhibit variable sequence and topology and define substrate binding sites and transport passageway, while the NBDs possess conserved sequences and bind and hydrolyze ATP to provide the "power-stroke" for the transporters to translocate the specific substrates across the cellular membrane.7−17 The multidrug ABC membrane transporters can extrude chemotherapy agents out of bacteria or tumor cells, which causes multidrug resistance (MDR) and ineffective treatment of diseases, underscoring the importance of understanding their underlying mechanisms to design more effective therapy.1,18−22

Bacillus subtilis (a Gram-positive bacterium) is a widely used model organism to study multidrug ABC transporters. Current studies show that there are 78 ABC transporters in B. subtilis.23−25 BmrA (YvcC), the ABC transporter of B. subtilis, exhibits the highest homology to each half of P-gps (MDR1), HorA (40% identity), and LmrA (42% identity), which makes it an excellent choice to study multidrug ABC transporters.26 Fluoroquinolones (e.g., Oflox, norfloxacin, ciprofloxacin, levofloxacin, and gemifloxacin) are widely used antibiotics to treat a variety of respiratory and urinary tract infections, which include pneumonia, chronic bronchitis, and tuberculosis.27,28 The extensive use of conventional antibiotics has led to the development of multiantibiotics resistance and the creation of superbugs that cannot be effectively eradicated by traditional antibiotics; hence, there is an urgent need to design new types of antibiotics and unconventional drugs (e.g., nanomedicine) to treat the infections.

Noble metal nanoparticles (NPs) possess unique physicochemical properties. Their high surface-area-to-volume ratio

Article Recommendations
allows them to serve as effective drug carriers that offer high payloads, high permeability, high local target concentrations, and high binding affinity due to multivalence effects. Furthermore, the high surface-area-to-volume ratio of NPs could also lead to high chemical reactivity, and bare NPs themselves could serve as unconventional drugs to eradicate bacteria. In our previous studies, we found that Ag and Au NPs at low concentrations do not inhibit cell growth and are biocompatible, while a higher concentration of NPs was unstable in the buffer or medium, which led to the aggregation of bare NPs on the surface of the cellular membrane that causes cell death.

We have successfully imaged single Ag NPs in solution, in single live cells, and single embryos and used their size-dependent plasmonic optical properties to study size-dependent efflux functions of multidrug membrane transporters in single live cells (both Gram-positive and Gram-negative bacteria) in real time at nanometer resolution. We have also used their size-dependent plasmonic optical properties to characterize the mode of action of antibiotics, such as aztreonam and chloramphenicol, in single live cells. Therefore, the plasmonic NP-based drug carriers can serve as size-dependent photostable-sized imaging probes to study size-dependent efflux kinetics of multidrug membrane transporters and size-dependent MDR in situ in real time, while nanocarriers are inhibiting the bacterial growth.

In our previous study, we have designed, synthesized, purified, and characterized three different sized antibiotic nanocarriers and developed cell culture medium, in which P. aeruginosa (Gram-negative bacteria) cells grew and functioned normally and the nanocarriers remained unchanged (stable, nonaggregated). We found that their inhibitory effect against two strains of P. aeruginosa, WT (normal expression of MexAB-OprM) and ΔABM (deletion of MexAB-OprM), highly depends upon the NP size, antibiotic dose, and multidrug membrane transporter (MexAB-OprM) expression. In this study, we used the same nanocarriers to study the dependence of inhibitory effect of the antibiotic nanocarriers against Gram-positive bacteria, two strains of B. subtilis (Gram-positive bacteria), WT (normal expression of BmRA) and ΔBmRA (deletion of bmrA), upon the size of nanocarriers, and dose of antibiotics (Oflx). Note that MexAB-OprM and BmRA are two completely different types of multidrug membrane transporters, energized by proton gradients across the cellular membrane and ATP hydrolysis, respectively. Further, P. aeruginosa are Gram-negative bacteria, while B. subtilis are Gram-positive bacteria, and they have very different cellular envelop structures. By comparing these two studies, we aim to understand the dependence of inhibitory effects of nanocarriers upon the types of multidrug membrane transporters and the types of bacteria.

Results and Discussion

Synthesis, Purification, and Characterization of Stable Drug Nanocarriers. We synthesized, purified, and characterized 2.4 ± 0.7, 13.0 ± 3.1, and 92.6 ± 4.4 nm Ag NPs. We used the thiol group of 11-amino-1-undecanethiol hydrochloride (AUT) to attach a monolayer of AUT (MUNH₂) onto surface of NPs to prepare AgMUNH₂ NPs and then linking the amine group of 11-amino-1-undecanethiol with the carboxyl group of Oflx via peptide bonds using 1-ethyl-3-[3-dimethylaminopropyl]-carbodiimide hydrochloride (EDC) and sulfo-N-hydroxysulfosuccinimide (NHS) as mediators to generate AgMUNH₂-Oflx NPs (antibiotic drug nanocarriers).
and dynamic light scattering (DLS), NMR, and UV–vis spectroscopy, respectively.\textsuperscript{30} We used DLS and UV–vis spectroscopy to study the stability (nonaggregation) of antibiotic drug nanocarriers with desired concentrations in a commonly used standard Lysogeny broth (LB) medium (1% tryptone, 0.5% yeast extract, and 0.5% NaCl in deionized (DI) water, pH = 7.2) in the shaker (MaxQ 5000, 200 rpm, 37 °C) for 12 h. We found that they were aggregated.\textsuperscript{30} The aggregation of nanocarriers would alter their sites and cause potential precipitation of nanocarriers from the medium that would reduce their doses and make the study of dose- and size-dependent unreliable. Therefore, we modified the cell culture medium by reducing the NaCl concentration from 0.5 to 0.1% and found that the drug nanocarriers with desired concentrations in the modified LB medium (1% tryptone, 0.5% yeast extract, and 0.1% NaCl in DI water, pH = 7.2) were stable (nonaggregated) under the cell culture condition and duration, in the shaker (MaxQ 5000, 200 rpm, 37 °C) for 12 h.

Characterization of Cellular Functions in the Modified Medium. We characterized the viability and efflux function of the cells cultured in the modified medium to make certain that the modified cell culture medium can be used to culture healthy and well-functional cells as those cultured in the standard cell culture medium. We precultured the cells (WT-BmrA and ΔBmrA) in the standard medium for 12 h, then cultured the precultured cells in the standard medium and the modified medium, and followed the cell growth over time. The growth curves of the cells cultured in the standard medium (Figure 2a) and the modified medium (Figure 2b) for WT (Figure 2A) and ΔBmrA (Figure 2B) are the same, showing that the cells grow normally in the modified cell culture medium.

We then used live/dead BacLight assay to determine the viability of the cells, which had been cultured in the standard and modified media over 17 h. For live/dead BacLight assay,\textsuperscript{52} green fluorescent dye (SYTO9, λ\textsubscript{max} = 520 nm) stains only live cells, while a red fluorescent dye (propidium iodide, λ\textsubscript{max} = 610 nm) can only diffuse into the dead cells because of disintegrated cellular membranes of dead cells. Thus, the live cells exhibit green fluorescent, while dead cells display red fluorescent. The results in Figure 3 show that more than 97% of the cells cultured in both media over 17 h. For live/dead BacLight assay, we used DLS and UV–vis spectroscopy to study the stability (nonaggregation) of antibiotic drug nanocarriers with desired concentrations in a commonly used standard Lysogeny broth (LB) medium (1% tryptone, 0.5% yeast extract, and 0.5% NaCl in deionized (DI) water, pH = 7.2) in the shaker (MaxQ 5000, 200 rpm, 37 °C) for 12 h.

Characterization of Cellular Functions in the Modified Medium. We characterized the viability and efflux function of the cells cultured in the modified medium to make certain that the modified cell culture medium can be used to culture healthy and well-functional cells as those cultured in the standard cell culture medium. We precultured the cells (WT-BmrA and ΔBmrA) in the standard medium for 12 h, then cultured the precultured cells in the standard medium and the modified medium, and followed the cell growth over time. The growth curves of the cells cultured in the standard medium (Figure 2a) and the modified medium (Figure 2b) for WT (Figure 2A) and ΔBmrA (Figure 2B) are the same, showing that the cells grow normally in the modified cell culture medium.

Figure 2. Study of the suitability of the modified LB medium to culture (A) WT and ΔBmrA: the cellular growth curves of (A) WT and (B) ΔBmrA cultured in (a) standard and (b) modified LB media over time show that the growth rates of a given strain in either medium are nearly identical, which indicates that the modified LB medium can be used to culture both WT and ΔBmrA cells.

Figure 3. Study of the viability of the cells (WT and ΔBmrA) cultured in (a) standard and (b) modified LB medium using live/dead BacLight assay. (A) Optical and (B) fluorescence images of the cells (e.g., WT) that were cultured over 12 h and suspended in the phosphate-buffered saline (PBS) buffer and assayed using live/dead BacLight assay. The cells exhibiting green fluorescence and red fluorescence are counted as live and dead cells, respectively. (C) Plot of the percent of the live cells (number of live cells divided by the total number of the cells) cultured in (a) standard and (b) modified LB media shows that more than 97% of the cells (WT and ΔBmrA) are viable, which further demonstrates that the modified LB medium can be used to culture the cells. The scale bar is 5 μm.
molecules in the WT than in ΔBmrA cells. The results show the high BmrA-dependent efflux kinetics of intracellular dye in live cells that were cultured in both standard and modified cell culture media (Figure 4A,B), respectively. The efflux kinetics of cells cultured in the standard medium (Figure 4A) are similar to those cells cultured in the modified medium, further demonstrating that the modified cell culture medium is well suitable to culture WT and ΔBmrA cells that preserve the efflux function of multidrug BmrA membrane transporters.

**Study of Antibiotic Dose, NP Size, and BmrA Expression-Dependent Inhibitory Effects.** We measured minimal inhibitory concentration (MIC) of Oflx attached onto the nanocarriers to determine whether inhibitory effects of antibiotic nanocarriers against the growth of WT-BmrA and ΔBmrA depend on the NP size, Oflx dose, and BmrA expression. The cells (WT or ΔBmrA) were cultured in the modified LB medium containing a dilution series of free Oflx alone, each type of the given sized drug nanocarriers (AgMUNH–Oflx NPs) and AgMUNH2 NPs (absence of Oflx, control experiment), and the cell growth was measured over time.

The dilution series contains 0, 0.055, 0.11, 0.22, 0.42, and 0.72 μM of free Oflx (Figure 5A,E) or Oflx carried by the NPs (AgMUNH–Oflx NPs) for WT-BmrA (Figure 5B–D) and ΔBmrA (Figure 5F–H), respectively. The corresponding concentrations of nanocarriers (NP concentration) are (Figure 5B: a–f) 0, 0.06, 0.13, 0.26, 0.49, and 0.83 nM for (2.4 ± 0.7) nm NPs with a conjugation ratio of 8.6 × 10^3 Oflx molecules per NP; (Figure 5C: a–f) 0, 5.8 × 10^3, 1.2 × 10^2, 2.3 × 10^2, 4.5 × 10^2, and 7.6 × 10^2 nM for (13.0 ± 3.1) nm NPs with a conjugation ratio of 9.4 × 10^3 Oflx molecules per NP; (Figure 5D: a–f) 0, 8.4 × 10^3, 1.7 × 10^4, 3.4 × 10^4, 6.4 × 10^4, and 1.1 × 10^5 nM for (92.6 ± 4.4) nm NPs with a conjugation ratio of 6.5 × 10^5 Oflx molecules per NP, respectively. The control experiments include the cells cultured with the LB medium alone (blank control, Figure 5A,E: a) or the medium containing 0.83 nM, 7.6 × 10^2 nM, or 1.1 pM AgMUNH2 NPs (in the absence of Oflx) for 2.4 ± 0.7, 13.0 ± 3.1, or 92.6 ± 4.4 nm NPs, which are the same concentrations of the NPs of nanocarriers as those in (f) for each type of NPs (B–D and F–H), respectively.

**Figure 4.** Characterization of the efflux function of membrane transporter (BmrA) in WT and ΔBmrA cells cultured in (A) standard and (B) modified LB medium. Time-dependent fluorescence intensity of 2 μM Hoechst dye incubated with the cells (OD_600 nm = 0.1) in PBS buffer, pH 7.2: (a) WT and (b) ΔBmrA cultured in (A) standard and (B) modified LB media show nearly identical accumulation and efflux kinetics, demonstrating that the modified LB medium possess well-functional efflux pump and the modified LB medium can be used to culture the cells for the study of accumulation and efflux kinetics of B. subtilis.

**Figure 5.** Study of the dependence of inhibitory effects of antibiotic nanocarriers (AgMUNH–Oflx NPs) against the growth of (A–D) WT and (E–H) ΔBmrA cells upon antibiotic dose, NP size, and BmrA expression. Photographs of the LB medium cultured with (A–D) the WT cells and (E–H) ΔBmrA containing (a–f) 0, 0.055, 0.11, 0.22, 0.42, and 0.72 μM of (A and E) unconjugated free Oflx alone. (a–f) 0, 0.055, 0.11, 0.22, 0.42, and 0.72 μM of the Oflx conjugated with the Ag NPs of (B and F) 2.4 ± 0.7, (C and G) 13.0 ± 3.1, and (D and H) 92.6 ± 4.4 nm in diameters, respectively. The concentrations of Oflx conjugated onto the NPs are determined using their labeling ratios. The blank control experiments include the concentrations of AgMUNH2 NPs in (a) of (B–D and F–H) containing 0.83 nM, 7.6 × 10^2 nM, or 1.1 pM AgMUNH2 NPs (in the absence of Oflx) for 2.4 ± 0.7, 13.0 ± 3.1, or 92.6 ± 4.4 nm NPs, which are the same concentrations of the NPs of nanocarriers as those in (f) for each type of NPs (B–D and F–H), respectively.
the concentration of Ofx alone or Ofx covalently conjugated with a given sized antibiotic drug nanocarrier to determine the MIC of Ofx for each cell strain (Figure 6). The result shows that the inhibitory effects of Ofx highly depend on the dose of Ofx and size of the nanocarriers but not on the cellular expression of BmrA.

![Figure 6](image)

Figure 6. Study of dose-, size-, and BmrA-dependent MICs of antibiotic nanocarriers (AgMUNH–Ofx NPs) against (A) WT and (B) ΔBmrA cells. Plots of normalized OD₆₀₀ nm of the cells cultured for 17 h in the modified LB medium containing (a–c) AgMUNH₂ NPs (absence of Ofx control), (d) Ofx alone, and (e–g) Ofx linked with (e) 2.4 ± 0.7, (f) 13.0 ± 3.1, and (g) 92.6 ± 4.4 nm Ag NPs, respectively. The concentrations of AgMUNH₂ NPs in (a–c) of (A) and (B) are the same as the given sized nanocarriers with the highest Ofx concentrations in (e–g) for each type of NPs in (A) and (B), but without Ofx (control experiments for the study of effects of NPs), respectively. The experimental data (points) are fitted with an equation $y = a e^{-b x}$, solid line as follows: (A): (d) $y = 1.12 e^{-3.02x}$, $R^2 = 0.918$; (e) $y = 1.10 e^{-1.96x}$, $R^2 = 0.841$; (f) $y = 1.11 e^{-6.33x}$, $R^2 = 0.881$; (g) $y = 1.00 e^{-5.54x}$, $R^2 = 1.000$. (B): (d) $y = 1.12 e^{-5.55x}$, $R^2 = 0.922$; (e) $y = 1.10 e^{-1.96x}$, $R^2 = 0.712$; (f) $y = 1.09 e^{-7.09x}$, $R^2 = 0.906$; (g) $y = 1.00 e^{-12.01x}$, $R^2 = 1.000$. The MICs (MIC₅₀) of free Ofx and linked Ofx were determined at the half of the maximum of the normalized OD₆₀₀ nm for each curve (solid line).

Control experiments (Figure 6: a–c) show that the OD₆₀₀ nm of the cell suspension incubated with each of three different sized AgMUNH₂ NPs (absence of Ofx) are nearly independent of the NP concentration and nearly the same as those cultured in the medium alone. The result indicates that the given concentration of AgMUNH₂ NPs does not generate significant inhibitory effects against the growth of WT and ΔBmrA cells. Note that the NP concentration is the same as that of the highest concentration of the given sized nanocarriers, respectively. The studies have shown that the bare noble metal NPs (Ag NPs) themselves can inhibit the growth of bacteria in a concentration-dependent manner. The NPs that are functionalized with the surface molecules (e.g., peptides) exhibit biocompatibility of the surface molecules, instead of the bare NPs. Thus, the biocompatibility of AgMUNH₂ NPs that we observed in the study is most likely attributed to the surface functional molecules (MUNH₂) that are attached on the surface of the NPs.

On the contrary, the OD₆₀₀ nm of the cell suspension incubated with Ofx alone or Ofx attached onto the given sized nanocarriers decrease as Ofx concentration increases, showing that their inhibitory effects against the growth of WT and ΔBmrA cells highly depend upon the dose of Ofx and size of nanocarriers (Figure 6A,B: d–f). We fitted the experimental data with an exponential decay equation ($y = a e^{-b x}$), which represents the inhibitory effect upon the exponential cell growth. We define the concentration of Ofx needed to reduce the growth of the cells in the medium alone to the half as the MIC of Ofx. The results of MICs are summarized in Table 1, showing that the MICs of free Ofx and Ofx attached onto the nanocarriers highly depend upon the dose of Ofx and the size of nanocarriers but not the cellular expression of BmrA.

For free Ofx alone (Figure 6A,B: d), the OD₆₀₀ nm of the cell suspension decrease with the Ofx concentration, showing the MICs of 0.16 ± 0.00 and 0.17 ± 0.02 μM Ofx for the WT and ΔBmrA cells, respectively.

Interestingly, for 2.4 ± 0.7 nm drug nanocarriers with a conjugation ratio of 8.6 × 10² Ofx molecules/NP (Figure 6A,B: e), the OD₆₀₀ nm of the cell suspension decrease with the Ofx concentration less rapidly than those of free Ofx and two other larger nanocarriers. Notably, for 13.0 ± 3.1 nm drug nanocarriers with a conjugation ratio of 9.4 × 10³ Ofx molecules/NP (Figure 6A,B: f), the OD₆₀₀ nm of the cell suspension decreases with the Ofx concentration are nearly the same as those of free Ofx, showing the nearly identical inhibitory and MICs of 0.12 ± 0.01 and 0.11 ± 0.01 μM Ofx for the WT and ΔBmrA cells, respectively. For 92.6 ± 4.4 nm drug nanocarriers with a conjugation ratio of 6.5 × 10⁵ Ofx molecules/NP (Figure 6A,B: g), the OD₆₀₀ nm of the cell suspension decrease with the Ofx concentration the most rapidly, showing the highest inhibitory effects and the lowest MICs of 0.012 ± 0.001 and 0.012 ± 0.001 μM Ofx for the WT and ΔBmrA cells, respectively.

The MICs of either free Ofx or Ofx attached onto nanocarriers for WT-BmrA and ΔBmrA cells are the same, suggesting that either form of Ofx could be extruded out of the cells by other membrane transporters in both WT-BmrA and ΔBmrA. In other words, Ofx is not a specific substrate of

### Table 1. Study of Dependence of MIC of Ofx upon the Size of Nanocarriers and Expression of BmrA of Two Strains of *B. subtilis* (WT and ΔBmrA)

<table>
<thead>
<tr>
<th>MIC₅₀ of Ofx (μM)</th>
<th>WT</th>
<th>ΔBmrA</th>
</tr>
</thead>
<tbody>
<tr>
<td>free Ofx alone</td>
<td>0.16 ± 0.00</td>
<td>0.17 ± 0.02</td>
</tr>
<tr>
<td>nanocarriers (2.4 ± 0.7 nm)</td>
<td>0.40 ± 0.02</td>
<td>0.49 ± 0.03</td>
</tr>
<tr>
<td>nanocarriers (13.0 ± 3.1 nm)</td>
<td>0.12 ± 0.01</td>
<td>0.11 ± 0.01</td>
</tr>
<tr>
<td>nanocarriers (92.6 ± 4.4 nm)</td>
<td>0.012 ± 0.001</td>
<td>0.012 ± 0.001</td>
</tr>
</tbody>
</table>

*The experimental data were fitted using the exponential decay equation ($y = a e^{-b x}$) to determine the parameters (a and b) with the highest regression. The MIC of Ofx for each sample was determined at the half of the cell growth of the blank control experiment (Figure 6).*
BmrA, and other membrane transporters are primary forces to extrude the Oflx out of the cells, which leads to the insignificant (or masked) contribution of BmrA and the BmrA-independent MICs of Oflx.

**Comparison of Both Studies and Distinctive Findings.** By comparing the results in this study with our previous study, we found that Oflx attached onto the nanocarriers retains its efficacy (inhibitory effect) against both Gram-positive bacteria (*B. subtilis*) and Gram-negative bacteria (*P. aeruginosa*). Inhibitory effects of nanocarriers against both strains of bacteria highly depend upon the size of nanocarriers, further demonstrating that the closed-packed Oflx molecules on the NPs (multivalence) could increase local drug dose, enhance their binding affinity with the target, and offer higher potency against both *B. subtilis* and *P. aeruginosa*. Notably, the inhibitory effects of nanocarriers are not linearly proportional to their sizes. For example, the smallest antibiotic nanocarriers (2.4 ± 0.7 nm) show the lowest inhibitory effects and the highest MICs against both strains than free Oflx, while the mid-sized nanocarriers (13.0 ± 3.1 nm) display the nearly identical inhibitory effects and MICs as free Oflx, and the largest antibiotic nanocarriers (92.6 ± 4.4 nm) exhibit the highest inhibitory effects and the lowest MICs against both strains.

The primary difference between both studies is their inhibitory effects on two different types of the cells (*B. subtilis* and *P. aeruginosa*) and their dependence on the efflux pump. For the previous study, the inhibitory effects of nanocarriers highly depend upon the expression of MexAB-OprM (multidrug membrane transporter) of *P. aeruginosa* (Gram-negative bacterium). In this study, they are independent upon the expression of BmrA (multidrug membrane transporter) of *B. subtilis* (Gram-positive bacterium). Therefore, the inhibitory effects of nanocarriers against bacteria show the selectivity, suggesting the possibility of using them as medicines. Notably, all three sized nanocarriers can enter *B. subtilis* (Gram-positive bacteria) and *P. aeruginosa* (Gram-negative bacteria), even though *B. subtilis* (Gram-positive bacteria) possess a very different envelop structure from *P. aeruginosa* (Gram-negative bacteria), suggesting potential common applications against bacteria. Further, the results demonstrate that antibiotic drug nanocarriers show specificity toward the given membrane transporters and their potentially wide utility against both Gram-positive and Gram-negative bacteria.

**SUMMARY**

In summary, we have successfully used three different sized antibiotic drug nanocarriers (AgMUNH–Oflx NPs) to study their size-dependent inhibitory effects against Gram-positive bacteria (*Bacillus subtilis*, WT-BmrA, and ΔBmrA). We have designed a modified cell culture medium, which enables the WT-BmrA and ΔBmrA cells to grow normally and the antibiotic drug nanocarriers to be stable (nonaggregated) in the medium over the entire duration of cell culture (17 h). Thus, the size and dose of nanocarriers remain unchanged during their incubation with the cells for 17 h, enabling us to study the size- and dose-dependent effects of the drug nanocarriers on the cell growth and efflux function of BmrA. Control experiments of three sized AgMUNH₂ NPs (absence of Oflx) show insignificant inhibitory effects toward WT-BmrA and ΔBmrA, which are likely attributed to the surface functional molecules (MUNH₂) attached onto the NPs. The significant findings include that (i) the largest nanocarriers create the highest inhibitory effects, while the smallest nanocarriers generate the lowest inhibitory effects, demonstrating that the same number of antibiotic molecules (Oflx) that are carried and delivered by the larger NPs can produce the higher inhibitory effects. These results indicate that the closed-packed Oflx molecules on the surface of NPs might strengthen their binding affinity with the target (multivalence) and provide larger payload to increase local targeting dose, leading to the higher potency. (ii) The inhibitory effects of Oflx depend upon the multivalent local targeting effects, as well as their intracellular distribution and concentrations. (iii) Their inhibitory effects do not significantly depend upon the cellular expression of multidrug BmrA membrane transporter, suggesting that other transporters in ΔBmrA could effectively extrude the antibiotic nanocarriers out of the ΔBmrA cells, leading to the same MICs as WT-BmrA. These findings show that the inhibitory effects of nanocarriers are not linearly proportional to their sizes, suggesting the possibility for one to design the optimal-sized nanocarriers to create the most potent effect of antibiotics against a specific given bacterial strain and to potentially evade a specific given multidrug membrane transporter. Efforts are being made to identify the specific membrane transporters that are responsible for the extrusion of drug nanocarriers out of WT-BmrA and ΔBmrA cells and to study their underlying molecular mechanisms.

**MATERIALS AND METHODS**

**Characterization of Cell Culture.** We used two strains of Gram-positive bacterial cells (*B. subtilis*): WT (normal expression BmrA) and ΔBmrA previously named as ΔYvcC (a mutant strain that is devoid of the bmrA, also named as ΔyvcC or ΔbmrA) that were isogenic strains and provided by Jault. The cells were first precultured in a commonly used standard LB medium (1% tryptone, 0.5% yeast extract, and 0.5% NaCl in DI water, pH = 7.2) in a shaker (MaxQ5000, 200 rpm, 37 °C) for 12 h. The precultured cells (20 μL) were then further cultured in the 2 mL standard LB medium or the modified LB medium (1% tryptone, 0.5% yeast extract, and 0.1% NaCl in DI water, pH = 7.2) in a shaker (MaxQ5000, 200 rpm, 37 °C) for another 17 h. The cell growth curves were determined by measuring the OD₆₀₀ nm of cell suspension in the medium over 17 h of cell culture. The cell suspension was diluted to the OD₆₀₀ nm of cell suspension below 0.2 and measured.

By the end of cell culture, we used live/dead BacLight viability and counting assay (Invitrogen) to assay the viability of the cultured cells. We used dark-field optical microscopy and epi-fluorescence microscopy to image the cells in a microchamber containing the medium. We acquired the green and red fluorescence cell images and counted them as live and dead cells, respectively.

By the end of the cell culture, we used centrifugation to harvest the cells (Beckman JA-14, 7500 rpm) and rinsed the cells with the PBS buffer (0.5 mM phosphate buffer, 1.5 mM NaCl, pH 7.0) three times. We suspended the cells in the PBS buffer and adjusted to a desired cell suspension concentration (OD₆₀₀ nm = 0.1) in the buffer. We continuously measured the fluorescence intensity of Hoechst 3342 dye (Invitrogen) of the cell suspension (OD₆₀₀ nm = 0.1) containing 2 μM of the dye at a 3 s time interval for 2 h using a fluorescence spectrometer (PerkinElmer L550B) with excitation and emission wavelengths at 350 and 488 nm, respectively.
Synthesis, Purification, and Characterization of Drug Nanocarriers. We synthesized and characterized the antibiotic drug nanocarriers, as reported previously. Briefly, we synthesized, purified, and characterized (2.4 ± 0.7), (13.0 ± 3.1), and (92.6 ± 4.4) nm Ag NPs, as reported previously. We used centrifugation to thoroughly wash the NPs three times with DI water immediately after the synthesis. We used UV–vis spectroscopy (Hitachi U-2010), dark-field optical microscopy and spectroscopy (DFOMS), high-resolution transmission electron microscopy (JEOL, JEM-2100F), and dynamic light scattering (DLS) (Nicomp 380ZLS particle sizing system) to measure the NP concentrations, the LSPR images, the spectra of single NPs, and the sizes of single NPs, respectively. We used the interaction of thiol groups of MUNH2 with the NPs to attach 11-aminooxy-1-undecanethiohydrochloride (MUNH2, AUT, 99%, Sigma-Aldrich) onto the surface of NPs to prepare functional AgMUNH2 NPs. We used centrifugation (Beckman Optima L90k, 4 °C) to wash the AgMUNH2 NPs thoroughly with DI water three times to remove excess MUNH2. We used a two-step method via 1-ethyl-3-[3-dimethylaminopropyl]-carbodiimide (EDC) and N-hydroxysulfo succinimide (NHS) as mediators to link the amine groups of each sized AgMUNH2 NPs with the carboxyl group of Oflx via peptide bonds (Figure 1). We used centrifugation to wash the nanocarriers with DI water to purify the drug nanocarriers (AgMUNH–Oflx NPs) and stored them at 4 °C for future use. We used UV–vis spectroscopy, DFOMS, and DLS to characterize the concentrations, optical properties, and sizes of each sized AgMUNH2 NPs, respectively.

We used UV–vis absorbance spectra of Oflx at 288 nm and the plasmonic absorption spectra of the NPs to measure the molar concentration of Oflx and NPs, respectively. We then divided the molar concentrations of Oflx molecules on the surface of the nanocarriers by the molar concentration of the NPs to determine the molar labeling ratios of antibiotics (Oflx) to NPs for each sized drug nanocarriers.

Study of Stability of Drug Nanocarriers in Cell Culture Medium. We used UV–vis absorption spectroscopy, DLS, and dark-field optical microscopy and spectroscopy to characterize the concentration, size, and optical properties of nanocarriers and studied their stability (nonaggregation) in the commonly used standard LB medium and the modified medium over 24 h, respectively. We found that the given concentrations of 2.4 ± 0.7, 13.0 ± 3.1, and 92.6 ± 4.4 nm nanocarriers (6.0 nM, 0.8 nM, and 7 pM) are stable (nonaggregated) in the modified medium over 24 h, but they are unstable (aggregated) in the standard medium.

Characterization of Dose- and Size-Dependent Inhibitory Effects of Nanocarriers. The cells (WT or ΔBmrA) were precultured in the standard LB medium overnight and then cultured in the modified LB medium (2.5 mL) containing a dilution series of free Oflx alone, given sized drug nanocarriers (AgMUNH–Oflx NPs), and AgMUNH2 NPs (control experiments) by inoculating 104 precultured cells into the medium in a shaker (200 rpm, 37 °C) over 17 h.

The dilution series of 0, 0.055, 0.11, 0.22, 0.42, and 0.72 μM free Oflx or Oflx conjugated with the NPs (AgMUNH–Oflx NPs) were prepared in the modified cell culture medium to culture WT and ΔBmrA (Figure 5). They are correlated with the drug nanocarrier (NP) concentrations: (i) 0, 0.06, 0.13, 0.26, 0.49, and 0.83 nM for (2.4 ± 0.7) nm NPs with a conjugation ratio of 8.6 × 102 Oflx molecules per NP; (ii) 5.8 × 103, 1.2 × 102, 2.3 × 102, 4.6 × 102, and 7.6 × 102 nM for (13.0 ± 3.1) nm NPs with a conjugation ratio of 9.4 × 103 Oflx molecules per NP; and (iii) 8.4 × 102, 1.7 × 103, 3.4 × 103, 6.4 × 103, and 1.11 pM for (92.6 ± 4.4) nm NPs with a conjugation ratio of 6.5 × 104 Oflx molecules per NP. The control experiments include the modified LB medium only (blank control) and containing 0.83 nM, 7.6 × 102 nM, or 1.1 pM AgMUNH2 NPs (in the absence of Oflx) for 2.4 ± 0.7, 13.0 ± 3.1, or 26.4 ± 4.4 nM NPs, respectively.

We quantitatively determined the OD600 nm of the cell suspension in a 96-well plate using a plate reader (BioTek Synergy HT) equipped with a UV–vis absorption spectral detector at 5, 11, and 17 h. We plotted the OD600 nm of each cell suspension at 17 h versus Oflx concentration (free Oflx or Oflx attached onto the nanocarrier) to determine their inhibitory effects (MIC). Specifically, we normalized the OD600 nm of each cell suspension with the maximum OD600 nm (the cells cultured in the medium alone, blank control), respectively. We plotted the normalized OD600 nm of the cell suspension versus the concentration of free Oflx (Oflx alone) or the concentration of Oflx attached onto a given sized drug nanocarrier. We used the exponential decay (\(y = a e^{-bx}\)) to fit the experimental data and to determine the parameters \((a, b)\) of the equation with the highest possible regression. The MIC50 (the concentration of Oflx at which the cell growth was inhibited to the half of the cell growth of the blank control experiment) was then determined. Unlike conventional semiquantitative methods to estimate the MICs using solid culture plates (a colony-forming unit), we developed this new approach to quantitatively determine the MICs using the dilution series of antibiotics or antibiotic nanocarriers in the liquid LB medium and mathematically fitting the experimental data. Further, the dilution series of antibiotics in the liquid LB medium enabled the nanocarriers to be well dispersed and avoided the aggregation of nanocarriers in the solid culture plates and allowed us to characterize the stability of nanocarriers in the liquid medium in real time at single NP resolution.

ASSOCIATED CONTENT
Supporting Information
The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsomega.9b03698.

Growth curve of WT-BmrA cells incubated with (A) free Oflx, (B) 2.4 ± 0.7, (C) 13.0 ± 3.1, and (D) 92.6 ± 4.4 nm Oflx nanocarriers, and AgMUNH2 NPs (in the absence of Oflx, control experiment) (Figure S1); and growth curve of ΔBmrA cells incubated with (A) free Oflx, (B) 2.4 ± 0.7, (C) 13.0 ± 3.1, and (D) 92.6 ± 4.4 nm Oflx nanocarriers, and AgMUNH2 NPs (in the absence of Oflx, control experiment) (Figure S2) (PDF).

AUTHOR INFORMATION
Corresponding Author
Xiao-Hong Nancy Xu − Old Dominion University,
Norfolk, Virginia; orcid.org/0000-0002-7470-1948;
Phone: (757) 683-5698; Email: xhxu@odu.edu;
www.odu.edu/~xhxu

Downloaded from https://dx.doi.org/10.1021/acsomega.9b03698
ACS Omega 2020, 5, 1625−1633
Associated Content
Supporting Information
The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsomega.9b03698.

Copyright 2020 American Chemical Society
Other Authors
Pavan Kumar Cherukuri – Old Dominion University, Norfolk, Virginia
Preeyaporn Songkiatsak – Old Dominion University, Norfolk, Virginia
Feng Ding – Old Dominion University, Norfolk, Virginia
Jean-Michel Jault – UMR5086 CNRS/UCBLyon 1, MMSB-IBCP, Lyon, France

Complete contact information is available at: https://pubs.acs.org/10.1021/acsomega.9b03698

Author Contributions
§P.K.C, P.S., and F.D. contributed equally to this work.

Notes
The authors declare no competing financial interest.

ACKNOWLEDGMENTS
This work was supported, in part, by NSF (CBET 0507036 and 1450936) and NIH (R01 GM0764401, R21HL127580, and R15GM119116). All work was done in the Xu Lab. J-M.J. provided ΔBmrA (also called as ΔyvcC or ΔbmrA) cells and discussion. The authors thank Tao Huang for participating in the synthesis and characterization of nanocarriers.

REFERENCES


